While t(4;14) MMCLs and patient samples exhibit notable sensitivity to statins (47), our data extend statin utility to non-t(4;14) multiple myeloma by combination with BH3 mimetics where PUMA, NOXA, and ATF4 are biomarkers for statin sensitivity. Here, ATF4 is linked to AL amyloidosis.